188399-46-4

Basic information

• Product Name: 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1R,3S,4R)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-
• Synonyms: 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1R,3S,4R)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-;2-Amino-1,9-dihydro-9-[(1R,3S,4R)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one;[1R-(1α,3α,4β)]-2-AMino-1,9-dihydro-9-[4-hydroxy-3-(hydroxyMethyl)-2-Methylenecyclopentyl]-6H-purin-6-one;ent-Entecavir;2-Amino-9-((1R,3S,4R)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-1H-purin-6(9H)-one;Entecavir Enantiomer (1R,3S,4R);2-amino-9-((1R,3S,4R)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-1,9-dihydro-6H-purin-6-one;(1R,3S,4R)-Entecavir
• CAS NO: 188399-46-4
• Molecular Formula: C12H15N5O3
• Molecular Weight: 277
• Mol File: 188399-46-4.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.81
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 9?+-.0.20(Predicted)
• CAS DataBase Reference: 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1R,3S,4R)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1R,3S,4R)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-(188399-46-4)
• EPA Substance Registry System: 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1R,3S,4R)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-(188399-46-4)

Safety Data

• Hazardous Substances Data: 188399-46-4(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

ent-Entecavir is an enantiomeric impurity of the antiviral drug Entecavir (E558900).

Upstream product

• 1435752-36-5 ((1R,3R,5S)-5-acetoxy-3-(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methyl 4-nitrobenzoate 
• 1435752-42-3 ((1R,3R,5S)-5-acetoxy-3-hydroxy-2-methylenecyclopentyl)methyl 4-nitrobenzoate 
• 1435752-48-9 ((1R,3S,5S)-5-acetoxy-3-(2-amino-6-chloro-9H-purin-9-yl)-2-methylenecyclopentyl)methyl 4-nitrobenzoate 
• 10310-21-1 2-Amino-6-chloropurin 
• 1435752-55-8 ((1R,3S,5S)-5-acetoxy-3-(2-amino-6-oxo-1H-purin-9(6H)-yl)-2-methylenecyclopentyl)methyl 4-nitrobenzoate 
• 1383812-10-9 ((1R,3R,5S)-5-acetoxy-3-(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methyl acetate 
• 1383812-22-3 ((1 R,3S,5S)-5-acetoxy-3-(2-amino-6-chloro-9H-purin-9-yl)-2-methylenecyclopentyl)methyl acetate 
• 701278-65-1 (1S,2R,4R)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)-3-methylenecyclopentanol 
• 1383812-06-3 (1S,2R,4R)-4-(tert-butyldimethylsilyloxy)-2-(hydroxymethyl)-3-methylenecyclopentyl acetate 
• 1383812-02-9 (1S,3R)-3-(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-ynyl acetate 
• 1383811-94-6 (3S,5R)-5-(tert-butyldimethylsilyloxy)hept-1-en-6-yn-3-ol 
• 1383811-90-2 (3S,5R)-5-(tert-butyldimethylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yn-3-ol 
• 1383811-86-6 (3S,5R)-7-(trimethylsilyl)hept-1-en-6-yne-3,5-diol 
• 1383811-98-0 (1S,3R)-3-(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-yn-1-ol 

Relevant articles and documents

Process for preparing entecavir and intermediates thereof

It comprises the preparation of entecavir of formula (I), or a pharmaceutically acceptable salt thereof, or a hydrate thereof by submitting a compound of formula (III) where X is an halogen selected from Cl, Br, and I, first to a hydrolysis reaction using formic acid and then to a deprotection reaction, and isolating the entecavir either as free base or as a pharmaceutically acceptable salt. It also comprises intermediates which intervene in this preparation process.